Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term thymopentin treatment in systemic scleroderma

C Danese1, E Zavattaro, L Calisi

  • 1Clinica Medica II, Università degli Studi di Roma La Sapienza, Italy.

Current Medical Research and Opinion
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study).

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.

The Journal of dermatological treatment·2019
Same author

Lifestyle changes in the management of adulthood and childhood obesity.

Minerva endocrinologica·2014
Same author

Analysis of human β-papillomavirus and Merkel cell polyomavirus infection in skin lesions and eyebrow hair bulbs from a cohort of patients with chronic lymphocytic leukaemia.

The British journal of dermatology·2014
Same author

Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio.

The British journal of dermatology·2014
Same author

Effects of physical exercise on the female reproductive system.

Minerva endocrinologica·2013
Same journal

Treatment patterns among pediatric and adult patients with ulcerative colitis in the United States: a retrospective cohort study.

Current medical research and opinion·2026
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
See all related articles

Thymopentin treatment for systemic scleroderma significantly reduced specific lymphocytes (CD16+, CD25+) and improved clinical symptoms in most patients. This suggests thymopentin can positively impact immune balance and disease progression.

Area of Science:

  • Immunology
  • Rheumatology
  • Clinical Medicine

Background:

  • Systemic scleroderma is an autoimmune disease characterized by immune dysregulation.
  • Investigating immunomodulatory therapies is crucial for managing scleroderma.
  • Thymopentin is a thymic peptide with known immunomodulatory properties.

Purpose of the Study:

  • To evaluate the effect of thymopentin on immunological status in systemic scleroderma patients.
  • To correlate immunological changes with clinical condition modifications.
  • To assess the long-term impact of thymopentin therapy.

Main Methods:

  • Nine systemic scleroderma patients received intravenous thymopentin for 5 weeks, repeated every 3 months for 1-5 years.
  • Lymphocytic sub-populations (CD16+, CD25+) were analyzed pre- and post-treatment cycles.

Related Experiment Videos

  • Clinical condition was assessed throughout the follow-up period.
  • A control group of healthy subjects was included for comparison.

    • Main Results:

    • A statistically significant decrease in CD16+ and CD25+ lymphocytes was observed after the first treatment cycle.
    • Seven out of nine patients showed clinical improvement by the end of the follow-up.
    • Thymopentin treatment led to a significant correction of imbalanced lymphocytic subsets.

    Conclusions:

    • Thymopentin treatment can induce significant changes in lymphocyte populations in systemic scleroderma patients.
    • These immunological modifications correlate with clinical improvements.
    • Thymopentin shows potential as a therapeutic agent for systemic scleroderma.